Joinn Laboratories publishes 2025 annual report

• Joinn Laboratories released its 2025 annual report, showing revenue pressure from lower project pricing while profitability improved on non-operating valuation gains.
• Order momentum strengthened, with order backlog near RMB 2.6 billion alongside newly signed orders around RMB 2.6 billion.
• Strategy shifted toward technology upgrade, accelerating AI use in pathology workflows while building New Approach Methodologies platforms such as organoids and microphysiological systems.
• Service scope widened beyond core non-clinical safety work into earlier drug discovery and clinical sample testing to offer more end-to-end development support.
• Capacity expansion advanced, with Suzhou Phase II facilities brought online while Guangzhou site infrastructure completed ahead of laboratory fit-out and ramp-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Joinn Laboratories China Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12134880), on April 29, 2026, and is solely responsible for the information contained therein.